Publications by authors named "M Mirabella"
Background: Eating disorders (EDs) are among the least studied mental disorders in individuals at clinical high risk for psychosis (CHR-P). The primary aim (a) of this systematic review and meta-analysis was to identify factors predicting ED diagnoses in CHR-P individuals. The secondary aim (b) was providing a comprehensive clinical description of individuals with both CHR-P and EDs/ED-related symptoms.
View Article and Find Full Text PDFEffect of alemtuzumab on fatigue, quality of life, and patient/caregiver-reported outcomes in relapsing-remitting multiple sclerosis-A real-world evidence study.
Mult Scler Relat Disord
December 2024
Background: Alemtuzumab is approved in the European Union for treating highly active relapsing-remitting multiple sclerosis (RRMS). Patient-reported outcomes measure the treatment impact on quality of life (QoL), including fatigue, a common symptom in multiple sclerosis (MS). Chronic diseases like MS also affect the patient's caregiver.
View Article and Find Full Text PDFThis paper addresses the growing importance of efficient street lighting management, driven by rising electricity costs and the need for municipalities to implement cost-effective solutions. Central to this study is the UNI 11248 Italian regulation, which extends the European EN 13201-1 standard introduced in 2016. These standards provide guidelines for designing, installing, operating, and maintaining lighting systems in pedestrian and vehicular traffic areas.
View Article and Find Full Text PDFArticle Synopsis
- The study investigates the effects of discontinuing dimethyl fumarate (DMF) during early pregnancy in women with multiple sclerosis (MS), analyzing 137 pregnancies from Italian MS Centers.
- Results show that disease activity typically decreases during pregnancy but increases postpartum; higher relapse rates before conception correlate with faster relapses after giving birth.
- Importantly, DMF exposure during early pregnancy did not negatively affect fetal outcomes, suggesting it is safe for the pregnancy context.
New therapies and vaccines changed the management of COVID-19. The aim of this retrospective study was to describe characteristics, in-hospital mortality and its predictors in patients with moderate/severe COVID-19, considering the 4 different pandemic waves and viral variants' prevalence from February 2020 to January 2022. Among 1135 patients included, 873 (77%) had at least one comorbidity, 177 (16%) were immunocompromised.
View Article and Find Full Text PDF